EGFR and non-small cell lung carcinoma: Notably, silencing CXCR7 not only reverses the resistance of epidermal growth factor receptor (EGFR)-mutant NSCLC cells to EGFR tyrosine kinase inhibitors (TKIs) but also promotes the transition of cancer cells to an epithelial phenotype [51].